Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


eISSN: 1643-3750

Get your full text copy in PDF

2-chlorodeoxyadenosine treatment of Waldenstrom's Macroglobulinemia- the analysis of own experience and the review of literature

Krzysztof Lewandowski, Jan Maciej Zaucha, Maria Bieniaszewska, Kazimierz HaƂaburda, Andrzej Hellmann

Med Sci Monit 2000; 6(4): CR740-745

ID: 508200

Background: The aim of the study was to evaluate the results of treatment of Waldenstrom's Macroglobulinemia with 2-chlorodeoxyadenosine. The evaluation was based on our own experience as well as on the data published previously in the literature.
Material/Methods: 25 patients with Waldenstrom's Macroglobulinemia (MW) were treated with 2-chlorodeoxyadenosine (2-CdA) at the dose of 0.14 mg/kg b.w. /day for five consecutive days as 2-hour intravenous infusions. Chemotherapy was repeated every 28 to 35 days.
Results:     In one case (4%) a complete remission and in 15 patients (60%) a partial remission was achieved. In 6 patients (24%) stabilization of the disease was observed while in 3 patients (12%) progression was noted during the treatment. As a result of the therapy, the mean monoclonal protein concentration decreased from 28.7 g/l (range 5.5-62.5 g/l) to 16.7 g/l (range 0-62.9 g/l) and the mean hemoglobin concentration increased from 10.6 g/dl (range 6.9-13.4) to 12.4 g/dl (range 8.2-14.8 g/dl).
Conclusions: Our own experience, as well as conclusions of other authors, confirm the effectiveness of 2-CdA in MW treatment. Both the results of treatment and intensity of side effects observed in our treatment group were comparable to those described in previous reports.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree